PCN103 How Much Price Component is Accounted for in State Drugs Purchase Decisions in Ukrainian Oncology?

Financial toxicity of surgical cancer treatment in LMICs: Implications for patients and health systems

Схоже за: Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer · Pharmaceutical Economics and Policy

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective

Схоже за: Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer · Pharmaceutical Economics and Policy

Experience of EU countries in organizing of the circulation and availability of medicines for the population

Схоже за: Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer · Pharmaceutical Economics and Policy

Cost minimization and budget impact analysis of the use of a new 6-month form of triptorelin in the treatment of patients with prostate cancer in Ukraine

Схоже за: Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer · Pharmaceutical Economics and Policy

The European Cancer Patient’s Bill of Rights, update and implementation 2016

Схоже за: Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer

Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course

Схоже за: Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer